Timing of feeding tube may protect muscle in esophageal cancer patients
NCT ID NCT06712706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines whether placing a feeding tube before chemotherapy helps prevent muscle loss in people with advanced esophageal cancer. About 60 adults receiving treatment with a goal to cure will be followed. Researchers will compare muscle mass at diagnosis, before surgery, and six months after surgery to see if early feeding tube placement makes a difference.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
60 people
The number who actually took part.
- Started
-
Nov 2024
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients treated between 2017 and 2024 in the single institution of the City Hospital Zürich Triemli and completed a 6-month follow-up or died by 31.12.2024.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients aged 18 years and above at the time of diagnosis. * Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment. * Patients who received an FJT either before neoadjuvant treatment or during definitive surgery. Exclusion Criteria: * Insufficient data for analysis * Written rejection of general consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stadtspital Zürich
Zurich, 8063, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a robotic exoskeleton rebuild aging legs?
- Patient's own blood turned into surgical glue to stop deadly leaks
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer